GlassScriptPhysician profile
Addam Masri
NPI 1851335327
$7,064.70
in general payments reported to CMS, 2019-2025
42 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $364 · 2021: $1,069 · 2022: $1,190 · 2023: $1,631 · 2024: $1,403 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,980 · Education: $94.55 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,980.28 |
| Education | $94.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $925.82 | 2021-2025 | Collagenase Santyl, Regranex, Stravix Pl |
| Lilly USA, LLC | $902.95 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $803.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $762.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.13 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $499.14 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $372.69 | 2021-2025 | |
| Glaxosmithkline, LLC. | $369.06 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Tris Pharma INC | $284.49 | 2023-2025 | Dyanavel Xr |
| Exact Sciences Corporation | $188.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $165.73 | 2022-2025 | |
| Medtronic, INC. | $157.11 | 2024 | Hawkone |
| Amgen INC. | $121.20 | 2022-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $77.67 | 2024 | Voquezna |
| Ibsa Pharma INC. | $63.20 | 2023-2024 | Tirosint, Licart, Licart |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Addam Masri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.